Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Observational Retrospective Study of Therapeutic Approaches and Clinical Outcomes in Real Clinical Practice in Russian Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Low Unresectable and/or Metastatic Breast Cancer

NCT05913440 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT05913440
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05913440 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Observational Retrospective Study of Therapeutic Approaches and Clinical Outcomes in Real Clinical Practice in Russian Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Low Unresectable and/or Metastatic Breast Cancer
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
May 30, 2023
Completion date
March 14, 2025
Enrollment
1,669 (actual)
Sites
40

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer